CRL · available-data snapshot
Charles River Laboratories International, Inc. (CRL): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Charles River Laboratories International, Inc. (CRL); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for CRL?
We do not publish a fair value for Charles River Laboratories International, Inc.. What we can say from its filings and market data is below.
What is CRL's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: recent price trend has been strong. Its weakest: growth is slow or negative.
- Value · 47 of 100
Cheaper than 47% of Healthcare companies in US
- Price vs worth · 27 of 100
- Quality · 36 of 100
More profitable than 36% of Healthcare companies in US
- Financial health · 19 of 100
Financially stronger than 19% of Healthcare companies in US
- Growth · 13 of 100
Growing faster than 13% of Healthcare companies in US
- Momentum · 86 of 100
Outperformed 86% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $301.12
- Market cap
- $14,
375, 009, 280 - 52-week high
- $333.30
- 52-week low
- $146.20
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Charles River Laboratories International, Inc. (CRL) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, CRL trades at a recent price of $301.12, a market capitalisation of about $14,375,009,280, sitting 83% of the way up its 52-week range ($146.20–$333.30), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing CRL's trading multiples against a sector benchmark. Here that gives Fwd P/E of 23.6× (richer than the peer median of 17.5×); P/B of 5.1× (cheaper than the peer median of 7.8×); P/S of 3.6× (cheaper than the peer median of 6.2×); EV/EBITDA of 20.3× (in line with the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. CRL shows a price-to-book (P/B) of 5.06 and book value of $59.50 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. CRL is in an up-trend (price above both its 50- and 200-day averages), trading -9.7% from its 52-week high. Over the past year the stock is +63.0%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
CRL vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | CRL | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 23.6× | 17.5× | richer than |
| P/B | 5.1× | 7.8× | cheaper than |
| P/S | 3.6× | 6.2× | cheaper than |
| EV/EBITDA | 20.3× | 18.5× | in line with |
What does Charles River Laboratories International, Inc. do?
What does it do?
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates in the Diagnostics & Research industry (Healthcare sector), headquartered in United States. The company employs roughly 18,300 people.
How does it make money?
The business turns $4.0B in annual revenue into profit. Out of every $100 of sales, about $15 is left as operating profit (operating margin of 15.1%), after a 35% gross margin on the products/services it sells. After all costs, taxes and interest, -6.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries moderate debt (1.1× equity), can just cover its short-term bills (1.3× current ratio), and is currently lossmaking.
Who at CRL filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Option exercise | $204,479.64 | Form 4 for Parisotto Shannon M (opens sec.gov in a new tab) | |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Open-market sale | $302,579.64 | Form 4 for Parisotto Shannon M (opens sec.gov in a new tab) | |
| Coleman Glenn | EVP & Chief Financial Officer | Open-market buy | $2,974.30 | Form 4 for Coleman Glenn (opens sec.gov in a new tab) | |
| FOSTER JAMES C | Director | Option exercise | $4,102,143.84 | Form 4 for FOSTER JAMES C (opens sec.gov in a new tab) | |
| FOSTER JAMES C | Director | Option exercise | $2,590,700.76 | Form 4 for FOSTER JAMES C (opens sec.gov in a new tab) | |
| FOSTER JAMES C | Director | Open-market sale | $10,068,300.00 | Form 4 for FOSTER JAMES C (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.